According to the new market research report "HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) - Global Forecast to 2025", published by MarketsandMarkets™, the HLA Typing for Transplant Market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%.

Browse in-depth TOC on "HLA Typing for Transplant Market"

141 – Tables

36 – Figures  

193 – Pages

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742

Key Market Players

Some prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), Care Dx (US), and Immucor, Inc. (US). An analysis of the developments in the HLA typing for the transplants market from 2016–2019 showed that product launches, expansions, agreements, partnerships, collaborations, and acquisitions were the most widely adopted growth strategies in the market.

Thermo Fisher Scientific is the leading player in the global HLA typing for the transplants market. The company has a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems reagents for molecular and non-molecular assay procedures, including HLA typing products for transplant. The company focuses on launching technologically advanced products to maintain its leadership in the HLA typing for the transplants industry. Furthermore, the company focuses on strengthening its revenue growth and brand positioning by adopting strategies such as acquisitions and expansions. Pertaining to this, Thermo Fisher Scientific acquired several companies to enhance its presence in the market further. These acquisitions enabled the company to expand and strengthen its genomic analysis product portfolio as well as develop innovative diagnostic technologies.

Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=96374742

QIAGEN ((Netherlands) holds a leading position in the HLA typing for the transplant industry due to its vast product portfolio in molecular diagnostics and analytics. Over the years, the company has focused on multiple growth strategies, such as agreements, collaborations, and product launches. Along with this, the company has maintained continuous leadership in the HLA typing for the transplants industry with its huge consumer base. It has also strengthened its RD capabilities for the development of innovative HLA typing products for transplants to expand its consumer base and offer novel products.

North America accounted for the largest share of the HLA typing for transplants market

North America accounted for the largest share of the HLA typing for the transplants market in 2019, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative transplant diagnostic products (includes HLA typing) coupled with ongoing advancements in the field of genomics and proteomics, recent discovery genetic biomarkers their clinical role in immunoassay testing, and the increasing prevalence of chronic and communicable diseases.

Key Questions Addressed by the Report:

• What are the growth opportunities related to the adoption of HLA typing for transplant products across significant regions in the future?
• Emerging countries show immense opportunities for the growth and adoption of HLA typing for transplant instruments, related reagents consumables, and software. Will this scenario continue in the next five years?
• Where will the advancements in products offered by various companies take the industry in the mid- to long-term?
• What are the newest trends and advancements in the HLA typing for the transplants market?

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742